Emerging data on the use of anti‐tumor necrosis factor‐alpha medications in pregnancy

Wiley - Tập 94 Số 8 - Trang 607-611 - 2012
Christina Chambers1,2, Diana Johnson1
1Department of Pediatrics, Division of Dysmorphology and Teratology, University of California–San Diego, La Jolla, California
2Division of Dysmorphology and Teratology, Departments of Pediatrics, Family and Preventive Medicine, and Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, 9500 Gilman Drive MC 0828, La Jolla, CA 92093

Tóm tắt

AbstractAnti‐tumor necrosis factor (TNF) α medications are used for the treatment of a number of autoimmune diseases. Evaluation of pregnancy safety for these medications is complicated by the contribution of the underlying maternal disease to adverse pregnancy outcomes, such as preterm delivery and reduced birth weight. Placental transport of these medications is thought to be minimal in the first trimester, thereby providing some reassurance regarding theoretical risks for congenital malformations. Available human exposure data are sparse; however, to date there has been no convincing evidence to support an increased risk for a specific pattern of major congenital malformations with any of the drugs in this group for which some data is currently available. As a result of the improvement of symptoms during pregnancy in some women with autoimmune diseases, it may be possible to discontinue treatment before or shortly after conception. However, in some cases the benefits of treatment and concerns for disease flares in pregnancy have warranted continued treatment during pregnancy. Because of the relatively long half‐life of these medications, and theoretical concerns for immune compromise of the infant following exposure in the latter two trimesters, some clinicians recommend discontinuation of treatment in the third trimester to avoid potentially prolonged infant exposure in the postpartum period. Currently ongoing controlled cohort studies for some of the TNF blocker medications will help to provide more definitive answers for clinicians and patients. Birth Defects Research (Part A) 94:607–611, 2012. © 2012 Wiley Periodicals, Inc.

Từ khóa


Tài liệu tham khảo

10.1016/j.autrev.2010.08.004

10.1111/j.1365-2133.2010.09899.x

10.1016/j.jbspin.2008.04.016

Carter JD, 2006, Tumor‐necrosis factor‐α inhibition and VATER association: a causal relationship? Case report, J Rheumatol, 33, 1014

10.3899/jrheum.080545

10.1002/art.27358

10.1016/j.crohns.2010.05.001

10.1002/ibd.21154

10.3899/jrheum.081083

Hultzsch S, 2011, Pregnancy outcomes after exposure to etanercept. Abstract presented at ENTIS meeting, Jerusalem, Israel, 31, 260

10.1111/j.1572-0241.2004.30186.x

10.1002/acr.20422

10.1016/j.cgh.2006.03.002

10.1038/ajg.2010.464

10.1111/j.1365-2036.2005.02405.x

10.1136/ard.2008.105924

10.1517/14740338.2012.630388

10.1111/j.1365-2036.2008.03648.x

10.1097/BOR.0b013e328344a732

10.1093/rheumatology/keq350

10.1002/bdrb.20201

10.1093/rheumatology/kel400

10.1007/s00393-010-0652-y

Schnitzler F, 2007, Intentional treatment with infliximab during pregnancy in women with inflammatory bowel disease, Gastroenterology, 132, A144

10.1002/ibd.21583

10.1023/A:1021740108284

10.1136/ard.2010.140822

10.1093/toxsci/kfr083

10.1002/art.30210

Weber‐Schoendorfer C, 2011, Pregnancy outcomes in women exposed to adalimumab or infliximab; the experience of the Berlin Institute for Clinical Teratology and Drug Risk Assessment in Pregnancy and Lactation, Abstract presented at ENTIS meeting, Jerusalem, Israel, 31, 267

10.1111/j.1365-2036.2011.04617.x

Thông tin
Thông tin xuất bản

Wiley

Tập 94 Số 8

607-611

Thông tin tác giả